Selected article for: "cell activation and NK cell activation"

Author: Hashemi, Elaheh; Malarkannan, Subramaniam
Title: Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance
  • Cord-id: k8n0vey4
  • Document date: 2020_6_12
  • ID: k8n0vey4
    Snippet: Natural killer (NK) cells belong to type 1 innate lymphoid cells (ILC1) and are essential in killing infected or transformed cells. NK cells mediate their effector functions using non-clonotypic germ-line-encoded activation receptors. The utilization of non-polymorphic and conserved activating receptors promoted the conceptual dogma that NK cells are homogeneous with limited but focused immune functions. However, emerging studies reveal that NK cells are highly heterogeneous with divergent immun
    Document: Natural killer (NK) cells belong to type 1 innate lymphoid cells (ILC1) and are essential in killing infected or transformed cells. NK cells mediate their effector functions using non-clonotypic germ-line-encoded activation receptors. The utilization of non-polymorphic and conserved activating receptors promoted the conceptual dogma that NK cells are homogeneous with limited but focused immune functions. However, emerging studies reveal that NK cells are highly heterogeneous with divergent immune functions. A distinct combination of several activation and inhibitory receptors form a diverse array of NK cell subsets in both humans and mice. Importantly, one of the central factors that determine NK cell heterogeneity and their divergent functions is their tissue residency. Decades of studies provided strong support that NK cells develop in the bone marrow. However, evolving evidence supports the notion that NK cells also develop and differentiate in tissues. Here, we summarize the molecular basis, phenotypic signatures, and functions of tissue-resident NK cells and compare them with conventional NK cells.

    Search related documents:
    Co phrase search for related documents
    • adaptive immune response and liver inflammation: 1
    • adaptive immune response and low dose response: 1, 2
    • adaptive immune response and low expression: 1, 2
    • adaptive immune response and low number: 1
    • adaptive immune response and lung cancer: 1
    • adaptive immune response and lung present: 1, 2, 3
    • adaptive immune response and lung resident: 1
    • adaptive immune response and lung spleen: 1, 2
    • adaptive immune response and lymph node: 1, 2, 3, 4, 5, 6
    • adaptive immune response and lymphocyte 10: 1
    • adaptive immune response and lymphoid organ: 1
    • adaptive immune response and lymphoid progenitor: 1, 2
    • adaptive immune response and lymphoid tissue: 1, 2
    • adaptive immune response innate and adhesion molecule: 1
    • adaptive immune response innate and low dose response: 1
    • adaptive immune response innate and lung cancer: 1
    • adaptive immune response innate and lung present: 1
    • adaptive immune response innate and lung spleen: 1
    • adaptive immune response innate and lymphoid tissue: 1